HSP70 Is a Critical Regulator of HSP90 Inhibitor's Effectiveness in Preventing HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis

Ruben M. L. Colunga Biancatelli,Pavel A. Solopov,Tierney Day,Betsy Gregory,Michael Osei-nkansah,Christiana Dimitropoulou,John D. Catravas

DOI: https://doi.org/10.3390/ijms25031920

IF: 5.6

2024-02-06

International Journal of Molecular Sciences

Abstract:Exposure to hydrochloric acid (HCl) can provoke acute and chronic lung injury. Because of its extensive production for industrial use, frequent accidental exposures occur, making HCl one of the top five chemicals causing inhalation injuries. There are no Food and Drug Administration (FDA)-approved treatments for HCl exposure. Heat shock protein 90 (HSP90) inhibitors modulate transforming growth factor-β (TGF-β) signaling and the development of chemical-induced pulmonary fibrosis. However, little is known on the role of Heat Shock Protein 70 (HSP70) during injury and treatment with HSP90 inhibitors. We hypothesized that administration of geranylgeranyl-acetone (GGA), an HSP70 inducer, or gefitinib (GFT), an HSP70 suppressant, alone or in combination with the HSP90 inhibitor, TAS-116, would improve or worsen, respectively, HCl-induced chronic lung injury in vivo and endothelial barrier dysfunction in vitro. GGA, alone, improved HCl-induced human lung microvascular endothelial cells (HLMVEC) barrier dysfunction and, in combination with TAS-116, improved the protective effect of TAS-116. In mice, GGA reduced HCl toxicity and while TAS-116 alone blocked HCl-induced chronic lung injury, co-administration with GGA, resulted in further improvement. Conversely, GFT potentiated HCl-induced barrier dysfunction and impaired the antidotal effects of TAS-116. We conclude that combined treatments with HSP90 inhibitors and HSP70 inducers may represent a novel therapeutic approach to manage HCl-induced chronic lung injury and pulmonary fibrosis.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper primarily explores the role of Heat Shock Protein 70 (HSP70) in preventing chronic lung injury and pulmonary fibrosis induced by hydrochloric acid (HCl). Specifically:

1. **Research Background**:
- Hydrochloric acid (HCl) is a widely used chemical in industry, often leading to accidental exposure.
- Currently, there are no FDA-approved drugs for treating long-term complications caused by HCl exposure.
- Heat Shock Protein 90 (HSP90) inhibitors can regulate the Transforming Growth Factor-β (TGF-β) signaling pathway, thereby affecting chemically induced pulmonary fibrosis.

2. **Research Hypothesis**:
- The researchers hypothesize that the use of HSP70 inducers (such as geranylgeranylacetone, GGA) or inhibitors (such as gefitinib, GFT), either alone or in combination with HSP90 inhibitors, can improve or worsen HCl-induced chronic lung injury and its associated endothelial barrier dysfunction in vivo and in vitro.

3. **Main Findings**:
- The study results indicate that GGA, an HSP70 inducer, can improve HCl-induced chronic lung injury, and its effect is enhanced when combined with the HSP90 inhibitor TAS-116.
- Conversely, GFT, an HSP70 inhibitor, exacerbates HCl-induced barrier dysfunction and weakens the therapeutic effect of TAS-116.
- The conclusion suggests that the combined use of HSP90 inhibitors and HSP70 inducers may represent a novel therapeutic approach for managing HCl-induced chronic lung injury and pulmonary fibrosis.

In summary, this paper aims to explore the potential of new therapeutic methods by studying the role of HSP70 in HCl-induced chronic lung injury and pulmonary fibrosis.